切换至 "中华医学电子期刊资源库"

中华普外科手术学杂志(电子版) ›› 2024, Vol. 18 ›› Issue (02) : 155 -159. doi: 10.3877/cma.j.issn.1674-3946.2024.02.011

论著

胃癌中ELK3蛋白的表达与临床病理特征和预后的关系研究
刘政宏1, 王凤力2,(), 吉亚君1, 高佳1   
  1. 1. 222002 江苏连云港,连云港市第一人民医院肿瘤科
    2. 222002 江苏连云港,连云港市第一人民医院胃肠外科
  • 收稿日期:2023-02-21 出版日期:2024-04-26
  • 通信作者: 王凤力

The relationship between the expression of ELK3 and clinicopathologic features and prognosis in gastric and paracancer tissues

Zhenghong Liu1, Fengli Wang2,(), Yajun Ji1, Jia Gao1   

  1. 1. Department of Oncology, the First People's Hospital of Lianyungang City, Lianyungang Jiangsu Province 222002,China
    2. Gastrointestinal Surgery, the First People's Hospital of Lianyungang City, Lianyungang Jiangsu Province 222002,China
  • Received:2023-02-21 Published:2024-04-26
  • Corresponding author: Fengli Wang
  • Supported by:
    2018 Annual Scientific Research Project of Jiangsu Provincial Health Commission(H2018091)
引用本文:

刘政宏, 王凤力, 吉亚君, 高佳. 胃癌中ELK3蛋白的表达与临床病理特征和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(02): 155-159.

Zhenghong Liu, Fengli Wang, Yajun Ji, Jia Gao. The relationship between the expression of ELK3 and clinicopathologic features and prognosis in gastric and paracancer tissues[J/OL]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(02): 155-159.

目的

探讨转录因子ELK3(ELK3)在胃癌组织和癌旁组织中的表达与临床病理特征及预后的关系。

方法

选取2019年1月至2021年6月行手术治疗的60例胃癌患者癌组织和对应癌旁组织(距肿瘤边缘3~5 cm)标本进行研究。采用免疫组织化学染色法检测胃癌组织及癌旁组织中ELK3表达情况。采用SPSS 21.0软件分析数据,计数资料以例表示,组间比较采用χ2检验;Kaplan-Meier生存函数分析ELK3与患者预后的关系;Cox回归模型分析影响胃癌患者预后生存的危险因素。P<0.05表示差异有统计学意义。

结果

胃癌组织中ELK3阳性表达率显著高于癌旁组织(χ2=11.422,P=0.001);胃癌组织中ELK3阳性表达率与淋巴结转移、肿瘤分期、分化程度、病理分型显著相关(P<0.05);60例胃癌患者均获得随访,中位随访时间25个月。ELK3阳性组患者累积总生存率显著低于ELK3阴性组(Log-Rank χ2=4.192,P=0.041);淋巴结转移、肿瘤分期、分化程度、神经侵犯、术后放化疗、ELK3阳性表达是影响胃癌患者预后的独立危险因素(P<0.05)。

结论

胃癌组织中ELK3显著阳性表达,与淋巴结转移、肿瘤分期、分化程度、病理分型等病理特征及患者预后关系密切,是影响胃癌患者预后的独立危险因素,可能成为胃癌预后评估的潜在生物标志物。

Objective

To analyze the relationship between the expression of transcription factor ELK3 (ELK3) and the clinicopathologic features and prognosis in gastric and paracancer tissues.

Methods

Samples of cancer tissues and corresponding paracancer tissues (3~5 cm away from tumor margin) from 60 patients with gastric cancer who underwent surgical treatment from January 2019 to June 2021 were selected for study. The expression of ELK3 in gastric cancer tissues and adjacent tissues was detected by immunohistochemical staining. SPSS 21.0 software was used to analyze the data, and the count data were presented as examples. χ2 test was used for comparison between groups. Kaplan-Meier survival function was used to analyze the relationship between ELK3 and prognosis. Cox regression model was used to analyze the risk factors affecting prognosis and survival of patients with gastric cancer. P<0.05 meant the difference was statistically significant.

Results

The positive expression rate of ELK3 in gastric cancer tissues was significantly higher than that in paracancer tissues (χ2=11.422, P=0.001). The positive expression rate of ELK3 in gastric cancer tissues was significantly correlated with lymph node metastasis, tumor stage, degree of differentiation and pathological classification (P<0.05). All 60 patients with gastric cancer were followed up for a median of 25 months.The cumulative overall survival rate of ELK3-positive group was significantly lower than that of ELK3-negative group (Log-Rank χ2=4.192, P=0.041). Lymph node metastasis, tumor stage, degree of differentiation, nerve invasion, postoperative chemoradiotherapy and positive expression of ELK3 were independent risk factors affecting the prognosis of gastric cancer patients (P<0.05).

Conclusion

The significant positive expression of ELK3 in gastric cancer tissues is closely related to pathological characteristics such as lymph node metastasis, tumor stage, differentiation degree, pathological type and patient prognosis. It is an independent risk factor affecting the prognosis of cancer patients, and may become a potential biomarker for the prognosis evaluation of gastric cancer.

图1 ELK3蛋白在胃癌组织中的表达 注:A=胃癌组织中ELK3蛋白阳性表达;B=癌旁组织中ELK3蛋白阴性表达
表1 胃癌组织中ELK3表达与临床病理特征的关系[例(%)]
图2 ELK3表达与胃癌患者预后的Kaplan-Meier生存曲线
表2 胃癌患者预后影响因素的单因素与多因素Cox回归分析
[1]
刘宗超,李哲轩,张阳,等. 2020全球癌症统计报告解读[J].肿瘤综合治疗电子杂志,2021,7(02):1-14.
[2]
蒋晓,张龙,尤玉成,等. 基于D2淋巴结清扫的两种术式治疗胃癌的近中期随访评价[J/CD].中华普外科手术学杂志(电子版),2021,15(06):650-652.
[3]
Ducker CShaw PE. Ubiquitin-Mediated Control of ETS Transcription Factors: Roles in Cancer and Development[J]. Int J Mol Sci,2021,22(10):5119.
[4]
Dazhi WZheng JChunling R. High ELK3 expression is associated with the VEGF-C/VEGFR-3 axis and gastric tumorigenesis and enhances infiltration of M2 macrophages[J]. Future Med Chem,2020,12(24):2209-2224.
[5]
Zhou LChen ZWu Y,et al. Prognostic signature composed of transcription factors accurately predicts the prognosis of gastric cancer patients[J]. Cancer Cell Int,2021,21(1):357.
[6]
Friedman BJ. Pitfall regarding expression of ETS-related gene(ERG)in fibrohistiocytic neoplasms[J]. J Cutan Pathol2021,48(7):1003-1004.
[7]
覃小珊,张彩灵,黄赞松. ETS转录因子家族在消化道肿瘤中的作用研究进展[J].中国医药科学,2020,10(16):26-31.
[8]
Li WOkabe AUsui G,et al. Activation of EHF via STAT3 phosphorylation by LMP2A in Epstein-Barr virus-positive gastric cancer[J]. Cancer Sci,2021,112(8):3349-3362.
[9]
Huang BChang CWang BL,et al. ELK1-induced upregulation of lncRNA TRPM2-AS promotes tumor progression in gastric cancer by regulating miR-195/ HMGA1 axis[J]. J Cell Biochem,2019,120(10):16921-16933.
[10]
Zheng LXu HDi Y,et al. ELK4 promotes the development of gastric cancer by inducing M2 polarization of macrophages through regulation of the KDM5A-PJA2-KSR1 axis[J]. J Transl Med,2021,19(1):342.
[11]
Teng YCang BMao F,et al. Expression of ETS1 in gastric epithelial cells positively regulate inflammatory response in Helicobacter pylori-associated gastritis[J]. Cell Death Dis,2020,11(7):498.
[12]
王文君,於宇,崔久嵬.肿瘤中ERG基因的表达及其临床研究进展[J].天津医药,2019,47(02):213-220.
[13]
Mei DQi YXia Y,et al. Microarray profile analysis identifies ETS1 as potential biomarker regulated by miR-23b and modulates TCF4 in gastric cancer[J]. World J Surg Oncol,2021,19(1):311.
[14]
王思贺. miR-155-5p和ELK3在胆囊癌组织中的表达及其临床意义[J].现代肿瘤医学,2020,28(10):1707-1711.
[15]
Yoo SMLee CJAn HJ,et al. RSK2-Mediated ELK3 Activation Enhances Cell Transformation and Breast Cancer Cell Growth by Regulation of c-fos Promoter Activity[J]. Int J Mol Sci,2019,20(8):1994.
[16]
陈应驹,彭和平,磨鹏诗,等. 胃癌患者淋巴结转移危险因素分析及患者预后分析[J/CD].中华普外科手术学杂志(电子版),2019,13(01):41-43.
[17]
Ichikawa MKEndo KItoh Y,et al. Ets family proteins regulate the EMT transcription factors Snail and ZEB in cancer cells[J]. FEBS Open Bio,2022,12(7):1353-1364.
[18]
Kim KSPark JIOh N,et al. ELK3 expressed in lymphatic endothelial cells promotes breast cancer progression and metastasis through exosomal miRNAs[J]. Sci Rep2019,9(1):8418.
[19]
Yang YCao LGuo Z,et al. Deubiquitinase UCHL5 stabilizes ELK3 to potentiate cancer stemness and tumor progression in pancreatic adenocarcinoma(PAAD)[J]. Exp Cell Res,2022,421(2):113402.
[1] 燕速, 霍博文. 腹腔镜食管胃结合部腺癌根治性切除术[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 13-13.
[2] 母德安, 李凯, 张志远, 张伟. 超微创器械辅助单孔腹腔镜下脾部分切除术[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 14-14.
[3] 李国新, 陈新华. 全腹腔镜下全胃切除术食管空肠吻合的临床研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 1-4.
[4] 李子禹, 卢信星, 李双喜, 陕飞. 食管胃结合部腺癌腹腔镜手术重建方式的选择[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 5-8.
[5] 李乐平, 张荣华, 商亮. 腹腔镜食管胃结合部腺癌根治淋巴结清扫策略[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 9-12.
[6] 陈方鹏, 杨大伟, 金从稳. 腹腔镜近端胃癌切除术联合改良食管胃吻合术重建His角对术后反流性食管炎的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 15-18.
[7] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[8] 李刘庆, 陈小翔, 吕成余. 全腹腔镜与腹腔镜辅助远端胃癌根治术治疗进展期胃癌的近中期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 23-26.
[9] 刘世君, 马杰, 师鲁静. 胃癌完整系膜切除术+标准D2根治术治疗进展期胃癌的近中期随访研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 27-30.
[10] 王庆亮, 党兮, 师凯, 刘波. 腹腔镜联合胆道子镜经胆囊管胆总管探查取石术[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(02): 313-313.
[11] 杨建辉, 段文斌, 马忠志, 卿宇豪. 腹腔镜下脾部分切除术[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(02): 314-314.
[12] 叶劲松, 刘驳强, 柳胜君, 吴浩然. 腹腔镜肝Ⅶ+Ⅷ段背侧段切除[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(02): 315-315.
[13] 郭兵, 王万里, 何凯, 黄汉生. 腹腔镜下肝门部胆管癌根治术[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(01): 143-143.
[14] 李凯, 陈淋, 苏怀东, 向涵, 张伟. 超微创器械在改良单孔腹腔镜巨大肝囊肿开窗引流及胆囊切除中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(01): 144-144.
[15] 魏丽霞, 张安澜, 周宝勇, 李明. 腹腔镜下Ⅲb型肝门部胆管癌根治术[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(01): 145-145.
阅读次数
全文


摘要